Alopecia Areata: Hair and Nail Findings in a Patient Undergoing Talquetamab Therapy for Multiple Myeloma

Talquetamab, a novel bispecific antibody used for treating relapsed or refractory multiple myeloma, has been associated with skin-related adverse events but not previously with hair pathology. This report discusses a 74-year-old female patient on talquetamab therapy who developed alopecic patches, nail changes, glossitis, and keratoderma. A scalp biopsy confirmed alopecia areata, which responded to betamethasone dipropionate gel. The case suggests that talquetamab may cause adverse cutaneous effects due to cross-reactivity with GPRC5D-expressing keratinized structures, indicating a need for further research into the pathogenesis and treatment of these side effects.